Table 1.
Clinical and demographic characteristics of study population.
| Characteristic | Aspirin (N = 909) | Non-aspirin (N = 909) | Total (N = 1,818) | Chi-squared | Risk ratio [95% CI] | p-value |
|---|---|---|---|---|---|---|
| Sex | 0.32 | 0.94 [0.78, 1.14] | .57 | |||
| Male | 454 (49.2) | 468 (50.7) | 922 (50.9) | |||
| Female | 439 (51.0) | 439 (48.9) | 896 (49.1) | |||
| Age, years | 74.29 ± 10.29 | 73.88 ± 12.78 | 73.43 ± 11.63 | .47 | ||
| Follow-up, years | 4.83 ± 1.31 | 4.931 ± 1.48 | 4.85 ± 1.49 | .43 | ||
| First creatinine, mg/dL | 2.24 ± 1.02 | 2.18 ± 1.04 | 2.21 ± 1.05 | .75 | ||
| Baseline eGFR, ml/min/1.73m2 | 32.56 ± 11.21 | 31.87 ± 11.26 | 31.52 ± 10.48 | .72 | ||
| CKD group | 2.4 | .76 | ||||
| Stage 3A | 79 (8.7) | 71 (7.8) | 177 (9.8) | |||
| Stage 3B | 366 (40.5) | 386 (42.5) | 888 (49.1) | |||
| Stage 4 | 355 (39.3) | 342 (37.6) | 642 (35.5) | |||
| Stage 5 | 103 (11.4) | 111 (12.2) | 103 (5.7) | |||
| Hypertension | 790 (86.9) | 778 (85.6) | 1568 (86.2) | 0.66 | 1.12 [0.86, 1.42] | .41 |
| Diabetes mellitus | 593 (65.2) | 478 (52.6) | 1071 (58.9) | 30.4 | 1.69 [1.40, 2.04] | < .01 |
| Atrial fibrillation | 71 (7.8) | 36 (4.0) | 107 (5.9) | 12.13 | 2.05 [1.36, 3.10] | < .01 |
Discrepancies between total number of patients, and number of patients for both groups are due to missing data.
Values are presented as absolute numbers (percentage) or as mean ± SD.